Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents MRCT in Royalty Monetization Deal

July 15, 2016

NEW YORK—Covington advised Medical Research Council Technology, a UK-based independent life science medical research charity, in its sale of a portion of the royalty stream associated with its cancer drug Keytruda® for $150 million (£115.6 million). 

Keytruda® (pembrolizumab), is a new generation treatment which stimulates the body’s immune system to fight cancer.

The Covington team consisted of partners John Gourary and Daniel Pavin, of counsel Morag Peberdy, and associate Rachel Beller.  The team was assisted by Robert Heller (U.S. tax), Guy Dingley (UK tax), Martin Beeler (bankruptcy), and Bruce Bennett and Ronald Hewitt (KYC issues).


Share this article: